Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

Furthermore, Eli Lilly’s pipeline in immunology and neuroscience also holds promise. Recent approvals like Omvoh for Crohn’s disease and ongoing development in areas like atopic dermatitis ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly (NYSE:LLY) reported its Q1 2025 earnings ... would force this big pharmaceutical to then rely on its other approved drugs like: Omvoh, Verzenio, Ebglyss, Jaypirca and Kisunla.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly and Company discovers ... and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized ...